TULSA-PRO® and Erectile Function
Erectile Dysfunction is one of the many risks a patient must consider when reviewing intervention options for their prostate condition. The TULSA Procedure aims to provide the patient with effective prostate tissue ablation without the harmful effects on sexual function associated with standard prostate interventions.
In addition to demonstrating the safety and efficacy of TULSA-PRO for whole gland ablation in 115 men with localized prostate cancer, the TACT Study evaluated a number of functional outcomes including erectile dysfunction.
The data now collected at 2 years (Figure 1.) demonstrates that TULSA-PRO has a low rate of erectile dysfunction:
- 24% moderate ED (Grade 2, medication indicated)
- 0% severe ED (Grade 3, medication not helpful)
- 83% maintained erections sufficient for penetration (IIEF question 2 ≥ 2)
Although the patients in this study all received a whole gland ablation, the TULSA-PRO System is designed to provide customized and predictable ablation of the physician defined region of the prostate, including partial gland ablation preserving unaffected parts of the prostate near the nerves involved in erectile function. The entirety of the procedure is completed while actively protecting critical structures such as the Urethra, Rectum, and Neurovascular bundles under the safety of real-time thermometry mapping.
For more information regarding the TACT study, please reference the following link: https://www.auajournals.org/doi/10.1097/JU.0000000000000860.02
To learn more about the TULSA-PRO System please visit: https://profoundmedical.com/new-tulsa/ or email info@profoundmedical.com
